US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 0.344
- -0.002-0.52%
Close Jan 17 16:00 ET
- 0.360
- +0.016+4.62%
Post 19:48 ET
17.07MMarket Cap-0.17P/E (TTM)
0.359High0.325Low896.02KVolume0.350Open0.346Pre Close303.06KTurnover2.16%Turnover RatioLossP/E (Static)49.63MShares4.17052wk High-0.20P/B14.24MFloat Cap0.30052wk Low--Dividend TTM41.41MShs Float71.500Historical High--Div YieldTTM9.72%Amplitude0.300Historical Low0.338Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
BioXcel Therapeutics Stock Forum
future of stock, medical is a new trend
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
📊⚡️📊
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share ("Comm...
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
Estimated 140 ...
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
No comment yet